Particularly, it is unclear whether the benefits of early oncological treatment, including radiotherapy, outweigh potential side-effects of acute and long-term toxicity, and which clinical or molecular factors optimally identify patients that are the best candidates for early oncological treatment or wait and watch approach.31 Postponing historical oncological treatments is a topical question with the arrival of IDH1/2 inhibitors for the treatment of gliomas, IDH-mutant. Here, IDH1 is linked to glioma.